In order to confirm such differential effect of Snol-A and Snin-I, we investigated dose-dependent response using more human cancer cells including osteosarcoma (U2OS; wild type p53 and Saos-2; null p53), ovarian adenocarcinoma (SKOV3; null p53), and breast adenocarcinoma (MDA-MB-231; mutant p53). This evidence concerns the gene TP53 and ovarian adenocarcinoma.